Physician profile
Mark Gabelman
NPI 1750371290
$3,339.13
in general payments reported to CMS, 2019-2025
27 companies · $747 in 2025
The $747 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $419 · 2020: $89.43 · 2021: $312 · 2022: $643 · 2023: $580 · 2024: $549 · 2025: $747.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,876.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,876.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $903.62 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $855.81 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $265.94 | 2021-2025 | Verquvo |
| Pfizer INC. | $227.14 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $168.55 | 2022-2025 | Lifevest |
| Abiomed | $130.98 | 2025 | |
| Astrazeneca Pharmaceuticals Lp | $117.88 | 2019-2024 | Farxiga |
| Amarin Pharma, INC. | $95.14 | 2019-2022 | |
| Philips North America LLC | $73.80 | 2022-2025 | Mcot |
| Bridgebio Pharma, INC. | $70.65 | 2025 | Attruby |
| E.R. Squibb & Sons, L.L.C. | $59.39 | 2021-2025 | Eliquis, Camzyos |
| Inspire Medical Systems, INC. | $48.23 | 2023 | Inspire |
| Angiodynamics, INC. | $34.62 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $34.42 | 2025 | |
| Heartflow, INC. | $32.61 | 2022-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $29.35 | 2020-2022 | |
| Vifor Pharma, INC. | $28.45 | 2021 | |
| Chiesi USA, INC. | $24.38 | 2025 | Juxtapid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.36 | 2025 | Jardiance |
| Lexicon Pharmaceuticals, INC. | $18.60 | 2023 | Inpefa |
| Irhythm Technologies, INC. | $18.45 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $14.92 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $14.57 | 2024 | Arcalyst |
| Astellas Pharma US INC | $14.44 | 2019 | |
| Allergan, INC. | $12.99 | 2019 | |
| Althera Pharmaceuticals LLC | $12.48 | 2021 | |
| Boston Scientific Corporation | $12.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Gabelman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.